Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostat... by Carlos E. Vargas, MD, Matthew Q. Schmidt, MD, Joshua R. Niska, MD, William F. Hartsell, MD, Sameer R. Keole, MD, Lucius Doh, MD, John Han-Chih Chang, MD, Christopher Sinesi, MD, Rossio Rodriquez, CTR, Mark Pankuch, PhD, Gary L. Larson, MD

Get full text